Search results for "Pharmacokinetic"

showing 10 items of 474 documents

Pharmacokinetic interaction between efavirenz and ketoconazole in rats

2009

It is well known that efavirenz and ketoconazole act as an inducer and inhibitor of CYP3A4, respectively. As a result of these actions, co-administration of these drugs may result in changes in the pharmacoki- netic parameters of one or both of them. 2. Duodenum-cannulated rats have been used to compare the effect of intraduodenal (KC i.d. ) and intrave- nous administration of ketoconazole (KC i.v. ) on the pharmacokinetics of efavirenz after intraduodenal administration, as well as the potential effect of efavirenz as a CYP450 inducer on ketoconazole phar - macokinetic profile. 3. While KC i.v. did not show any significant effect on efavirenz pharmacokinetic profile, KC i.d. increased sig-…

CyclopropanesMalemedicine.medical_specialtyAntifungal AgentsEfavirenzAnti-HIV AgentsHealth Toxicology and MutagenesisPharmacologyToxicologyBiochemistryEnteral administrationDrug Administration SchedulePeak concentrationchemistry.chemical_compoundCytochrome P-450 Enzyme SystemPharmacokineticsimmune system diseasesInternal medicinemedicineAnimalsCytochrome P-450 CYP3ACytochrome P-450 Enzyme InhibitorsDrug InteractionsInducerRats WistarPharmacologyCYP3A4Chemistryvirus diseasesGeneral MedicineBenzoxazinesRatsKetoconazoleEndocrinologyAlkynesKetoconazolePharmacokinetic interactionmedicine.drugXenobiotica
researchProduct

Inhibition of Efavirenz Metabolism by Sertraline and Nortriptyline and Their Effect on Efavirenz Plasma Concentrations.

2015

ABSTRACT Between 22 and 45% of HIV-positive subjects are likely to report symptoms of depression. Considering this background, a potential pharmacokinetic interaction between the nonnucleoside reverse transcriptase inhibitor efavirenz (EFV) and two antidepressants, sertraline (SRT) and nortriptyline (NT), was studied. Rats were administered EFV alone or together with the antidepressants, and changes in the plasma levels and pharmacokinetic parameters of EFV were analyzed. Additional in vitro experiments with rat and human hepatic microsomes were carried out to evaluate the inhibitory effect of SRT and NT on EFV metabolism by determining the formation rate of the major EFV metabolite (8-OH-E…

CyclopropanesMalemedicine.medical_specialtyEfavirenzAnti-HIV AgentsMetaboliteNortriptylinePharmacology030226 pharmacology & pharmacy03 medical and health scienceschemistry.chemical_compound0302 clinical medicinePharmacokineticsIn vivoInternal medicineSertralinemedicineAnimalsHumansPharmacology (medical)Drug Interactions030212 general & internal medicineRats WistarIC50PharmacologyChemistryAntidepressive AgentsBenzoxazinesInfectious DiseasesEndocrinologyAlkynesMicrosomeMicrosomes LiverReverse Transcriptase InhibitorsNortriptylinehuman activitiesDrug metabolismmedicine.drugAntimicrobial agents and chemotherapy
researchProduct

Contribution of CYP3A5 to the in vitro hepatic clearance of tacrolimus.

2005

Abstract Background: Tacrolimus is metabolized predominantly to 13-O-demethyltacrolimus in the liver and intestine by cytochrome P450 3A (CYP3A). Patients with high concentrations of CYP3A5, a CYP3A isoenzyme polymorphically produced in these organs, require higher doses of tacrolimus, but the exact mechanism of this association is unknown. Methods: cDNA-expressed CYP3A enzymes and a bank of human liver microsomes with known CYP3A4 and CYP3A5 content were used to investigate the contribution of CYP3A5 to the metabolism of tacrolimus to 13-O-demethyltacrolimus as quantified by liquid chromatography–tandem mass spectrometry. Results: Demethylation of tacrolimus to 13-O-demethyltacrolimus was …

DNA ComplementaryCYP3AClinical BiochemistryPharmacologyBiologyIn Vitro Techniques030226 pharmacology & pharmacyTacrolimus03 medical and health sciences0302 clinical medicinePharmacokineticsCytochrome P-450 Enzyme SystemCytochrome P-450 CYP3AHumansCYP3A7030304 developmental biologyDemethylation0303 health sciencesCYP3A4Biochemistry (medical)MetabolismTacrolimusMicrosomeMicrosomes LiverBaculoviridaeImmunosuppressive AgentsClinical chemistry
researchProduct

IMI – Oral biopharmaceutics tools project – Evaluation of bottom-up PBPK prediction success part 4: Prediction accuracy and software comparisons with…

2020

Oral drug absorption is a complex process depending on many factors, including the physicochemical properties of the drug, formulation characteristics and their interplay with gastrointestinal physiology and biology. Physiological-based pharmacokinetic (PBPK) models integrate all available information on gastro-intestinal system with drug and formulation data to predict oral drug absorption. The latter together with in vitro-in vivo extrapolation and other preclinical data on drug disposition can be used to predict plasma concentration-time profiles in silico. Despite recent successes of PBPK in many areas of drug development, an improvement in their utility for evaluating oral absorption i…

Data AnalysisPhysiologically based pharmacokinetic modellingDatabases FactualAdministration OralPharmaceutical Science02 engineering and technologyMachine learningcomputer.software_genreModels Biological030226 pharmacology & pharmacyBiopharmaceuticsPharmaceutical Sciences03 medical and health sciences0302 clinical medicineSoftwarePharmacokineticsHumansClinical Trials as Topicbusiness.industryCompound specificBiopharmaceuticsGeneral MedicineFarmaceutiska vetenskaper021001 nanoscience & nanotechnologyBioavailabilityIntestinal AbsorptionPharmaceutical PreparationsDrug developmentPerformance indicatorArtificial intelligence0210 nano-technologybusinesscomputerSoftwareForecastingBiotechnologyEuropean Journal of Pharmaceutics and Biopharmaceutics
researchProduct

Simultaneous determination of olanzapine, clozapine and demethylated metabolites in serum by on-line column-switching high-performance liquid chromat…

2001

An automated method for simultaneous routine quantification of the antipsychotic drugs clozapine, olanzapine and their demethylated metabolites is described. The method included adsorption on a cyanopropyl (CPS) coated clean-up column (10 microm; 10 x 2.0 mm I.D.), washing off interfering serum constituents to waste, and separation on C18 ODS Hypersil reversed phase material (5 microm; 250 x 4.6 mm I.D.) using acetonitrile-water-tetramethylethylenediamine (37:62.6:0.4, v/v/v) adjusted to pH 6.5 with concentrated acetic acid. UV-detection was performed at 254 nm. The limit of quantification was 10-20 ng/ml. Relative day to day standard variations ranged between 4.5 and 13.5%. The method is s…

Detection limitChromatographyChemistryMetaboliteReproducibility of ResultsGeneral ChemistryPirenzepineHigh-performance liquid chromatographySensitivity and SpecificityAcetic acidchemistry.chemical_compoundBenzodiazepinesAdsorptionPharmacokineticsOlanzapinemedicineHumansSpectrophotometry UltravioletQuantitative analysis (chemistry)ClozapineClozapineChromatography High Pressure Liquidmedicine.drugAntipsychotic AgentsJournal of chromatography. B, Biomedical sciences and applications
researchProduct

Automated Determination of Trimipramine and N-Desmethyl-Trimipramine in Human Plasma or Serum by HPLC With On-Line Solid Phase Extraction

1995

A fully automated method including column-switching and isocratic high performance liquid chromatography (HPLC) was developed for determination of the tricyclic antidepressant trimipramine (T) and its N-demethylated metabolite N-desmethyltrimipramine (DT). The limit of quantification was below 10 ng/ml for T and DT. The assay revealed linearity between detector response and drug concentration in a therapeutically relevant range of 10 to 500 ng/ml. The mean intra- and interassay variabilities were 6.2 and 12.3%, respectively, for T and 4.7 and 8.7% respectively, for DT. The method can be applied to therapeutic drug monitoring of patients under T therapy and may be useful for pharmacokinetic …

Detection limitChromatographymedicine.diagnostic_testMetaboliteDesmethylTrimipramineHigh-performance liquid chromatographychemistry.chemical_compoundPharmacokineticschemistryTherapeutic drug monitoringmedicineMolecular MedicineSolid phase extractionmedicine.drugJournal of Liquid Chromatography
researchProduct

Determination of sertraline in rat plasma by HPLC and fluorescence detection and its application toin vivopharmacokinetic studies

2012

A simple, rapid, and sensitive HPLC method based on 9H-fluoren-9-ylmethyl chloroformate derivatization for the quantification of sertraline in rat plasma has been developed, requiring a plasma sample of only 0.1 mL, which was deproteinized and derivatized for 5 min in two single steps. The obtained derivative was stable at room temperature and was determined by HPLC using a fluorescence detector. The analytical column was a C(18) column and the mobile phase was acetonitrile and water (80:20, v/v). Calibration curves were linear in the range of 10-500 ng/mL. The limit of detection was approximately 3 ng/mL, and the lower limit of quantification was established at 10 ng/mL. The bias of the me…

Detection limitchemistry.chemical_compoundChromatographyPharmacokineticsChemistryCalibration curveFiltration and SeparationDerivativeChloroformateDerivatizationHigh-performance liquid chromatographyFluorescence spectroscopyAnalytical ChemistryJournal of Separation Science
researchProduct

In vivo comparison of DOTA based 68Ga-labelled bisphosphonates for bone imaging in non-tumour models.

2013

Bone metastases are a class of cancerous metastases that result from the invasion of a tumor into bone. The solid mass which forms inside the bone is often associated with a constant dull ache and severe spikes in pain, which greatly reduce the quality of life of the patient. Numerous (99m)Tc-labeled bisphosphonate functionalised complexes are well established tracers for bone metastases imaging. The objective of this research was to evaluate the pharmacokinetics and behaviour of three DOTA based bisphosphonate functionalised ligands (BPAMD, BPAPD and BPPED), using both (68)Ga μ-PET in vivo imaging and ex vivo biodistribution studies in healthy Wistar rats. The compounds were labelled with …

Diagnostic ImagingMaleCancer ResearchBiodistributionmedicine.medical_treatmentGallium RadioisotopesBone and Boneschemistry.chemical_compoundHeterocyclic Compounds 1-RingPharmacokineticsIn vivomedicineDOTAAnimalsRadiology Nuclear Medicine and imagingRats WistarRadionuclide ImagingDiphosphonatesChemistrybusiness.industrySoft tissueBisphosphonateRatsRadiographyIsotope LabelingMolecular MedicineNuclear medicinebusinessPreclinical imagingEx vivoNuclear medicine and biology
researchProduct

Pharmacological distribution diagrams: a tool for de novo drug design.

1996

Abstract Discriminant analysis applied to SAR studies using topological descriptors allows us to plot frequency distribution diagrams: a function of the number of drugs within an interval of values of discriminant function vs. these values. We make use of these representations, pharmacological distribution diagrams (PDDs), in structurally heterogeneous groups where generally they adopt skewed Gaussian shapes or present several maxima. The maxima afford intervals of discrimianant function in which exists a good expectancy to find new active drugs. A set of β-blockers with contrasted activity has been selected to test the ability of PDDs as a visualizing technique, for the identification of n…

Distribution (number theory)GaussianAdrenergic beta-AntagonistsBiophysicsInterval (mathematics)Machine learningcomputer.software_genreBiochemistryPlot (graphics)symbols.namesakeDiscriminant function analysisComputer GraphicsPharmacokineticsMathematicsMolecular Structurebusiness.industryDiscriminant AnalysisPattern recognitionFunction (mathematics)Linear discriminant analysisDrug DesignsymbolsArtificial intelligenceMaximabusinesscomputerHalf-LifeJournal of molecular graphics
researchProduct

Biowaiver Monograph for Immediate-Release Solid Oral Dosage Forms: Sitagliptin Phosphate Monohydrate

2021

Sitagliptin is an antihyperglycemic drug used in adults for the treatment of diabetes Type 2. Literature data and in-house experiments were applied in this monograph to assess whether methods based on the Biopharmaceutics Classification System (BCS) could be used to assess the bioequivalence of solid immediate-release (IR) oral dosage forms containing sitagliptin phosphate monohydrate, as an alternative to a pharmacokinetic study in human volunteers. The solubility and permeability characteristics of sitagliptin were reviewed according to the BCS, along with dissolution, therapeutic index, therapeutic applications, pharmacokinetics, pharmacodynamic characteristics, reports of bioequivalence…

Dosage FormsDrugbusiness.industrymedia_common.quotation_subjectSitagliptin PhosphateAdministration OralBiological AvailabilityPharmaceutical SciencePharmacologyBioequivalenceBiopharmaceutics Classification SystemPermeabilityDosage formBiopharmaceuticsBioavailabilitySolubilityTherapeutic EquivalencyPharmacokineticsSitagliptinPharmacodynamicsmedicineHumansbusinessmedicine.drugmedia_commonJournal of Pharmaceutical Sciences
researchProduct